Barings LLC boosted its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 74.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,962 shares of the medical research company’s stock after acquiring an additional 8,070 shares during the quarter. Barings LLC’s holdings in Iqvia were worth $2,460,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC raised its stake in Iqvia by 19.4% during the second quarter. Steward Partners Investment Advisory LLC now owns 2,933 shares of the medical research company’s stock worth $293,000 after acquiring an additional 476 shares in the last quarter. IFM Investors Pty Ltd raised its stake in Iqvia by 5.4% during the third quarter. IFM Investors Pty Ltd now owns 9,290 shares of the medical research company’s stock worth $1,205,000 after acquiring an additional 478 shares in the last quarter. State Treasurer State of Michigan raised its stake in Iqvia by 1.0% during the third quarter. State Treasurer State of Michigan now owns 48,300 shares of the medical research company’s stock worth $6,266,000 after acquiring an additional 500 shares in the last quarter. Gateway Investment Advisers LLC raised its stake in Iqvia by 9.1% during the third quarter. Gateway Investment Advisers LLC now owns 6,770 shares of the medical research company’s stock worth $878,000 after acquiring an additional 563 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in shares of Iqvia by 6.7% in the second quarter. Louisiana State Employees Retirement System now owns 9,500 shares of the medical research company’s stock valued at $948,000 after buying an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 93.71% of the company’s stock.
Iqvia stock traded up $0.36 during mid-day trading on Thursday, hitting $116.21. The stock had a trading volume of 1,091,932 shares, compared to its average volume of 1,366,148. The stock has a market cap of $23.44 billion, a price-to-earnings ratio of 26.65, a P/E/G ratio of 1.66 and a beta of 0.81. Iqvia Holdings Inc has a 12 month low of $91.57 and a 12 month high of $135.48. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41.
Iqvia (NYSE:IQV) last posted its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.03. The business had revenue of $2.59 billion for the quarter, compared to analysts’ expectations of $2.58 billion. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business’s quarterly revenue was up 5.2% on a year-over-year basis. As a group, sell-side analysts expect that Iqvia Holdings Inc will post 5.13 EPS for the current year.
In other Iqvia news, insider Kevin C. Knightly sold 9,216 shares of the firm’s stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $126.46, for a total transaction of $1,165,455.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John G. Danhakl sold 370,470 shares of the firm’s stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total value of $46,245,770.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 601,586 shares of company stock worth $75,510,422. 6.00% of the stock is owned by company insiders.
A number of analysts have recently weighed in on the company. Argus set a $136.00 target price on Iqvia and gave the company a “buy” rating in a research note on Thursday, August 23rd. Piper Jaffray Companies restated a “hold” rating and issued a $97.00 target price on shares of Iqvia in a research note on Wednesday, July 25th. Barclays restated an “overweight” rating and issued a $130.00 target price (up from $120.00) on shares of Iqvia in a research note on Wednesday, July 25th. Bank of America upgraded Iqvia from a “neutral” rating to a “buy” rating and set a $135.00 target price for the company in a research note on Wednesday, July 25th. Finally, Raymond James raised their target price on Iqvia from $136.00 to $145.00 and gave the company a “strong-buy” rating in a research note on Friday, August 31st. Five analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Iqvia has an average rating of “Buy” and an average target price of $133.53.
TRADEMARK VIOLATION NOTICE: This news story was published by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://theenterpriseleader.com/2018/11/22/iqvia-holdings-inc-iqv-holdings-lifted-by-barings-llc.html.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Read More: Stock Symbols and CUSIP Explained
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.